Cart 2
  • Anti-PD1/PDCD1/CD279 antibody

Anti-PD1/PDCD1/CD279 antibody

Cat.#: 105846

Special Price 290.3 USD

Availability: In Stock
- +

Add to cart to get an online quotation

Product Information

  • Product Name
    Anti-PD1/PDCD1/CD279 antibody
  • Documents
  • Description
    monoclonal to PD1/PDCD1/CD279
  • Tested applications
  • Species reactivity
    Human PD1 / PDCD1 / CD279; KD of the antibody is 2.35E-10 M for PD1 (10377-H08H) as mesured by OCTET RED System.
    Has cross-reactivity with Rhesus PDCD1 (90305-K08H) in ELISA assay
    No cross-reactivity with mouse PDCD1 Protein (50124-M08H) and rat PDCD1 (80448-R08H) in ELISA assay
  • Alternative names
    CD279 antibody; CD279 antibody; hPD-1 antibody; hPD-l antibody; Ly101 antibody; PD1 antibody; PD-1 antibody; Pdc1 antibody; PDCD1 antibody; Pdcd1 antibody; SLEB2 antibody
  • Immunogen
  • Isotype
    Human IgG4
  • Preparation
    This antibody was a humanized antibody obtained from a mouse immunized with the recombinant Human PD1 / PDCD1 Protein (NP_005009.2; Met 1-Gln 167) and was produced using recombinant antibody technology.
  • Clonality
  • Formulation
    0.2 μm filtered solution in Histidine and Arginine buffer containing 120mM NaCl, 0.02% Tween 80, pH6.0
  • Storage instructions
    This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free.
    Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.
  • Applications
    Block - In a functional ELISA, 0.2 µg/mL of this antibody will block 50% of the binding of 0.2 µg/mL of Recombinant Human PD1 (Catalog 10377-H02H) to immobilized Recombinant Human PD-L1 Fc Chimera (Catalog 10084-H02H) coated at 10 µg/mL (100 µL/well). And >90% blocking effect can be obtained with 0.6 μg/mL of antibody.
    Neutralization - The neutralization activity of PD1 Neutralizing Antibody is Measured by its ability to neutralize PD1_PD-L1 pathway mediated inhibition of IFN-gamma secretion in the Mixed lymphocyte Reaction.
  • Validations

    PD1 / PDCD1 / CD279 Neutralizing Antibody

    PD1 / PDCD1 / CD279 Neutralizing Antibody

    Effect of Human PD1 HF06 antibody on IFN-gamma production in the Mixed Lymphocyte Reaction (MLR). Purified CD4T cells were cultured with allogeneic dendritic cell, as prepared by culturing monocytes in GM-CSF and IL-4 medium for seven days, in the medium containing serial concentrations of human PD1 HF06 antibody (Catalog 10377-HF06). Six days later, the IFNg secretion in the medium was measured using IFN-gamma Quantitative ELISA Kit.

  • Background
    Programmed cell death 1, also known as PDCD1, is a type I transmembrane glycoprotein, and is an immunoreceptor belonging to the CD28/CTLA-4 family negatively regulates antigen receptor signaling by recruiting protein tyrosine phosphatase, SHP-2 upon interacting with either of two ligands, PD-L1 or PD-L2. PD1 inhibits the T-cell proliferation and production of related cytokines including IL-1, IL-4, IL-10 and IFN-γ by suppressing the activation and transduction of PI3K/AKT pathway. In addition, coligation of PD1 inhibits BCR-mediating signal by dephosphorylating key signal transducer. PD1 has been suggested to be involved in lymphocyte clonal selection and peripheral tolerance, and thus contributes to the prevention of autoimmune diseases. Furthermore, PD1 is shown to be a regulator of virus-specific CD8+ T cell survival in HIV infection. As a cell surface molecule, PDCD1 regulates the adaptive immune response. Engagement of PD-1 by its ligands PD-L1 or PD-L2 transduces a signal that inhibits T-cell proliferation, cytokine production, and cytolytic function.
  • References
    • James ES, et al. (2005) PDCD1: a tissue-specific susceptibility locus for inherited inflammatory disorders. Genes Immun. 6(5): 430-7.
    • Okazaki T, et al. (2007) PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol. 19(7): 813-24.
    • del Rio ML, et al. (2008) PD-1/PD-L1, PD-1/PD-L2, and other co-inhibitory signaling pathways in transplantation. Transpl Int. 21(11): 1015-28.
    • Riley JL.(2009) PD-1 signaling in primary T cells. Immunol Rev. 229(1): 114-25.